RxDoctor Payments Data

Vinod Bhavnani, MD

Ophthalmology · Fort Myers, FLNPI 1437189701

Payments from drug & device makers

$5,095in general payments, 2019–2025

Across 271 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$796
  • Bausch & Lomb Americas Inc.$793
  • Aerie Pharmaceuticals, Inc.$273
  • Alcon$264
  • Sun Pharmaceutical Industries Inc.$250
  • plus $799 from 13 others

What the payments were for

  • Food & beverage$5,076100%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,095 in reported general payments places this provider in the 70th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$572,195
Medicare patients
1,171
Services billed
6,802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost798$468,340
RhopressaNetarsudil Mesylate100$67,881
CombiganBrimonidine Tartrate/Timolol140$66,449
VyzultaLatanoprostene Bunod65$43,395
RocklatanNetarsudil Mesylat/Latanoprost57$38,435
RestasisCyclosporine30$35,354
Alphagan PBrimonidine Tartrate66$33,799
XiidraLifitegrast28$33,272
Travoprost181$26,640
SimbrinzaBrinzolamide/Brimonidine Tart77$24,482
BesivanceBesifloxacin Hcl53$19,414
Latanoprost1,502$17,168
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol104$15,349
AzoptBrinzolamide21$14,893
ProlensaBromfenac Sodium40$14,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$1,920$603,9431,034 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$273$106,316157 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$793$76,66793 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa, Lotemax Sm$796$41,202123 claims
AlconSimbrinza, Azopt$264$39,37598 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →